New drug for chronic lymphocytic leukemia approved in Italy

Context

In brief

• New drug for chronic lymphocytic leukemia approved in Italy
• Pirtobrutinib reimbursable for relapsed or refractory patients
• Innovative treatment for advanced cases of CLL

Key facts

• What: Approval of pirtobrutinib for chronic lymphocytic leukemia
• When: March 26, 2026
• Where: Italy
• Who: Italian Medicines Agency (AIFA)
• Amount: Not specified

The Italian Medicines Agency (AIFA) has approved the reimbursability of pirtobrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The decision, published in the Official Gazette on March 26, 2026, makes the drug available for patients who have previously been treated with a covalent Bruton's tyrosine kinase (Btk) inhibitor. CLL is a hematological tumor characterized by an accumulation of B lymphocytes in the peripheral venous blood and lymphoid organs. In the West, CLL is the most common form of leukemia in adults, with an estimated incidence of 5 cases per 100,000 people. In Italy, approximately 3,000 new cases are estimated each year.

In-depth look at CLL

The disease is typical of advanced age, with 40% of diagnoses made after the age of 75 and only 15% before the age of 50. The average age at diagnosis is about 70 years, with a slight prevalence of men over women. Despite therapeutic advances, many patients with CLL experience multiple relapses or become resistant to treatment. Pirtobrutinib represents a significant therapeutic innovation, as it acts as a non-covalent Btk inhibitor and is capable of binding to the target protein differently from first- and second-generation covalent inhibitors.

Implications for cross-border workers

For cross-border workers who work in Switzerland and reside in Italy, the approval of this new drug could mean an additional treatment opportunity for patients with CLL. It is important that patients and their doctors are informed about the new therapeutic options available and the criteria for access to treatment with pirtobrutinib. Cross-border workers can benefit from an advanced Swiss healthcare system and an Italian healthcare system that now includes this new drug in its therapeutic offering.

Procedures for accessing treatment

To access treatment with pirtobrutinib, patients must be evaluated by their treating physicians. It is necessary that they have already exhausted standard therapeutic options with covalent Btk inhibitors. Patients must be followed by specialized centers and must comply with the reimbursability criteria established by AIFA. Cross-border workers can contact their general practitioners or specialists at oncological centers for further information and to initiate the evaluation process.

Comparison with existing therapies

Pirtobrutinib offers a unique and reversible mechanism of action, which distinguishes it from covalent Btk inhibitors. This new drug is able to overcome the molecular resistances that develop during previous treatments, offering a new and concrete opportunity for disease control with a very manageable safety profile. Clinical trial results have demonstrated the efficacy of the drug in a heavily pretreated patient population, showing durable clinical responses even in cases with a poor prognosis.

Expert quotes

“Approval of the reimbursability of pirtobrutinib represents a paradigm shift for patients with CLL who have already exhausted standard therapeutic options with covalent Btk inhibitors. Thanks to its unique and reversible mechanism of action, pirtobrutinib is able to overcome the molecular resistances that develop during previous treatments, offering a new and concrete opportunity for disease control with a very manageable safety profile,” comments Paolo Ghia, full professor of Medical Oncology at the Vita-Salute San Raffaele University of Milan.

Clinical studies

The results of the phase 1/2 clinical study Bruin, published in the ‘New England Journal of Medicine’ in 2023, demonstrated the efficacy of the drug in a heavily pretreated patient population. The phase 3 study Cll-Bruin 321 then compared pirtobrutinib with the standard reference treatment in the same setting, demonstrating its superiority in efficacy.

Conclusion

The approval of pirtobrutinib represents a significant step in the treatment of chronic lymphocytic leukemia, offering new hope to patients who have exhausted standard therapeutic options. For cross-border workers, this new therapeutic option can be a valuable opportunity to access advanced treatments and improve quality of life.

Operational details

Analysis of practical implications

The approval of pirtobrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in Italy opens new perspectives for patients with this disease. For cross-border workers who work in Switzerland and reside in Italy, this therapeutic novelty can have a significant impact on the management of their health.

Access to treatment for cross-border workers

Cross-border workers residing in Italy and working in Switzerland can benefit from the new drug pirtobrutinib, approved by AIFA. It is important that patients are aware of the access criteria and the procedures necessary to obtain the treatment. Patients must be evaluated by their treating physicians and must have exhausted standard therapeutic options with covalent Btk inhibitors.

Comparison with existing therapies

Pirtobrutinib represents a significant therapeutic innovation compared to first- and second-generation covalent Btk inhibitors. Its unique and reversible mechanism of action allows it to overcome the molecular resistances that develop during previous treatments. This offers patients a new opportunity to control the disease with a very manageable safety profile.

Procedures for accessing treatment

To access treatment with pirtobrutinib, patients must follow a specific procedure. First, they must be evaluated by their treating physicians to determine if they are eligible for the treatment. Subsequently, they must be followed by specialized centers that meet the reimbursability criteria established by AIFA. Patients must also provide detailed medical documentation and follow the treatment guidelines.

Implications for cross-border workers

For cross-border workers, access to treatment with pirtobrutinib can be facilitated by their residence in Italy and their work in Switzerland. Switzerland is known for its advanced healthcare system and the quality of its medical facilities. Cross-border workers can benefit from this combination of resources to access advanced treatments and improve their quality of life.

Comparison with the previous situation

Before the approval of pirtobrutinib, patients with relapsed or refractory CLL had few therapeutic options available. Covalent Btk inhibitors were often ineffective or caused molecular resistances. With the approval of pirtobrutinib, patients now have a new therapeutic option that offers a unique and reversible mechanism of action, improving their treatment prospects.

Usage scenario

Imagine a cross-border worker who works in Switzerland and resides in Italy. This cross-border worker has been diagnosed with relapsed or refractory CLL and has exhausted standard therapeutic options with covalent Btk inhibitors. Thanks to the approval of pirtobrutinib, the cross-border worker can now access this new treatment, improving their health prospects and quality of life. The cross-border worker can be followed by specialized centers in Italy and benefit from the advanced healthcare resources of Switzerland.

Conclusion

The approval of pirtobrutinib represents a significant step in the treatment of chronic lymphocytic leukemia, offering new hope to patients who have exhausted standard therapeutic options. For cross-border workers, this new therapeutic option can be a valuable opportunity to access advanced treatments and improve their quality of life.

Recommended tools

For an updated estimate, use the net salary calculator and the CHF-EUR exchange comparator.

Key points

Concrete actions for cross-border workers

For cross-border workers who wish to access treatment with pirtobrutinib, it is important to follow a series of concrete steps. These steps include medical evaluation, gathering the necessary documentation, and choosing a specialized center for treatment.

Steps to access treatment

1. Medical evaluation: The first step is to consult your primary care physician for an initial assessment. The doctor will determine if the patient is suitable for treatment with pirtobrutinib. 2. Gathering documentation: Once the patient has been evaluated and deemed suitable, it is necessary to gather all the required medical documentation. This documentation must include medical reports, test results, and any other relevant information. 3. Choosing a specialized center: The patient must choose a specialized center that meets the reimbursability criteria established by AIFA. These centers must be able to provide treatment with pirtobrutinib and follow the treatment guidelines. 4. Starting treatment: Once the patient has chosen a specialized center, they can start treatment with pirtobrutinib. The treatment must be carefully followed, and the patient must be regularly monitored to ensure that the treatment is effective and safe.

Useful tools

For cross-border workers who wish to obtain further information about treatment with pirtobrutinib, there are several useful tools available. These tools include cost calculators, treatment comparators, and practical guides for accessing treatment.

Cost calculator

A cost calculator can help patients estimate the cost of treatment with pirtobrutinib. This tool can be useful for planning medical expenses and ensuring that the treatment is accessible.

Treatment comparator

A treatment comparator can help patients compare the different treatments available for LLC. This tool can be useful for determining which treatment is most suitable for the patient's needs.

Practical guides

Practical guides can provide detailed information about the steps necessary to access treatment with pirtobrutinib. These guides may include information on how to gather the necessary documentation, how to choose a specialized center, and how to monitor the treatment.

Conclusion

The approval of pirtobrutinib represents a significant step in the treatment of chronic lymphocytic leukemia, offering new hope to patients who have exhausted standard therapeutic options. For cross-border workers, this new therapeutic option can be a valuable opportunity to access advanced treatments and improve their quality of life. By following the concrete steps described in this guide, cross-border workers can access treatment with pirtobrutinib and benefit from the new therapeutic opportunities available.

CTA

For more information and to access useful tools, visit our cost calculator and our treatment comparator.

Source: varesenoi.it